Format

Send to

Choose Destination
J Pediatr. 2012 May;160(5):790-5.e1. doi: 10.1016/j.jpeds.2011.10.026. Epub 2011 Dec 3.

A randomized, masked study of weekly erythropoietin dosing in preterm infants.

Author information

1
Department of Pediatrics, University of New Mexico, Albuquerque, NM, USA. rohls@salud.unm.edu

Abstract

OBJECTIVE:

To compare reticulocyte responses of once-per-week erythropoietin (EPO) dosing with 3-times-a-week dosing in preterm infants.

STUDY DESIGN:

Infants weighing ≤ 1500 g and ≥ 7 days of age were randomized to once-per-week EPO, 1200 U/kg/dose, or 3-times-a-week EPO, 400 U/kg/dose, subcutaneously for 4 weeks, along with iron and vitamin supplementation. Complete blood counts, absolute reticulocyte counts (ARCs), transfusions, phlebotomy losses, and adverse events were recorded.

RESULTS:

Twenty preterm infants (962 ± 55 g, 27.9 ± 0.4 weeks, 17 ± 3 days of age) were enrolled. Groups were similar at baseline. Infants in both groups had increased ARCs, which were similar between treatment groups at the start and end of 4 weeks. Hematocrit remained stable, and similar numbers of transfusions were administered. No adverse effects of either dosing schedule were noted.

CONCLUSIONS:

Preterm infants respond to weekly EPO by increasing ARCs and maintaining hematocrit. We speculate that once-per-week EPO dosing might be beneficial to preterm infants requiring increased erythropoiesis.

PMID:
22137666
PMCID:
PMC3598609
DOI:
10.1016/j.jpeds.2011.10.026
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center